Copyright
©The Author(s) 2016.
World J Gastrointest Pathophysiol. May 15, 2016; 7(2): 218-222
Published online May 15, 2016. doi: 10.4291/wjgp.v7.i2.218
Published online May 15, 2016. doi: 10.4291/wjgp.v7.i2.218
Tumour | Mesothelin expressions (%) | Comments | Ref. |
Pancreatic cancer | 86-100 | Co-expression of mesothelin and CA125 group associated with a poorer patient prognosis | [6,16,17] |
Gastric cancer | 29-59 | Luminal membrane expression is one of the poor prognostic factors | [6,18,27,35] |
Extrahepatic bile duct cancer | 72-100 | Luminal membrane expression or cytoplasmic expression of mesothelin could be a reliable prognostic factor | [6,21] |
Colorectal cancer | 28-58 | Luminal membrane expression was associated with lymphatic invasion | [6,20] |
Intraductal papillary mucinous neoplasm | 57 | Luminal membrane expression was correlated with the histological classification of the tumor and the recurrence rate | [19] |
- Citation: Einama T, Kawamata F, Kamachi H, Nishihara H, Homma S, Matsuzawa F, Mizukami T, Konishi Y, Tahara M, Kamiyama T, Hino O, Taketomi A, Todo S. Clinical impacts of mesothelin expression in gastrointestinal carcinomas. World J Gastrointest Pathophysiol 2016; 7(2): 218-222
- URL: https://www.wjgnet.com/2150-5330/full/v7/i2/218.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v7.i2.218